Physician profile
Princess Mark-Adjeli
NPI 1104351527
$585.30
in general payments reported to CMS, 2019-2025
12 companies · $99.99 in 2025
The $99.99 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $202 · 2021: $251 · 2024: $31.79 · 2025: $99.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.99 · Food and Beverage: $31.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.99 |
| Food and Beverage | $31.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $154.40 | 2020-2021 | |
| Seagen INC. | $128.10 | 2021-2025 | |
| Amgen INC. | $94.68 | 2021 | |
| Astellas Pharma US INC | $48.69 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.79 | 2024 | |
| Glaxosmithkline, LLC. | $22.42 | 2020 | |
| Abbvie INC. | $22.31 | 2020 | |
| Incyte Corporation | $19.68 | 2021 | |
| Genentech USA, INC. | $18.92 | 2020 | |
| Clovis Oncology, INC. | $15.86 | 2021 | |
| Epizyme, INC. | $14.42 | 2020 | |
| Lilly USA, LLC | $14.03 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Princess Mark-Adjeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.